# Gilead Sciences, Inc.  Share Price Target ‘$87.63’, now 17.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.share-price-target-87.63-now-17.8-upside-potential/4121142073
- Published: 2024-02-09T13:50:55+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) now have 24 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $116.00 and $69.00 and has a mean share price target
at $87.63. (at the time of writing). Given that the stocks previous close was at
$74.42 and the analysts are correct then we can expect a percentage increase in 
value of 17.8%. The 50 day moving average now sits at $80.41 while the 200 day moving
average is $78.18. The company has a market capitalization of 91.96B. The current
share price for the company is: $73.80 USD

 The potential market cap would be $108,280,823,270 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 16.4, revenue per share of $21.73
and a 9.87% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: